Physics:Deutetrabenazine
 | |
| Clinical data | |
|---|---|
| Trade names | Austedo |
| Other names | Tetrabenazine D6; SD809; SD-809 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a617022 |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C19H21D6NO3 |
| Molar mass | 323.462 g·mol−1 |
Deutetrabenazine (trade name Austedo) is a vesicular monoamine transporter 2 inhibitor which is used for the treatment of chorea associated with Huntington's disease and tardive dyskinesia.
Chemically, deutetrabenazine is an isotopic isomer of tetrabenazine in which six hydrogen atoms have been replaced by deuterium atoms. The incorporation of deuterium slows the rate of drug metabolism, allowing less frequent dosing.[3][4]
Efficacy
A Lancet study published on 28 June 2017 carried out a review between 29 October 2014 and 19 August 2016 where 298 patients were randomly assigned to receive at least one of the following: one dose of placebo per day, one dose of deutetrabenazine 12 mg/day, one dose of deutetrabenazine 24 mg/day, or one dose of deutetrabenazine 36 mg/day. From baseline to week 12, the least-squares mean AIMS (Abnormal Involuntary Movement Scale) score improved by −3.3 points in the deutetrabenazine 36 mg/day group, −3.2 points in the 24 mg/day group, −2.1 points in the 12 mg/day group, and −1.4 points in the placebo group. Deutetrabenazine 24 mg/day and 36 mg/day provided a significant reduction in tardive dyskinesia, with favourable safety and tolerability. These findings suggest that dosing regimens could be individualized and tailored for patients on the basis of dyskinesia control and tolerability.[5]
Pharmacology
Pharmacodynamics
Deutetrabenazine acts as a monoamine-depleting agent.[citation needed]
History
Teva Pharmaceuticals received approval from the Food and Drug Administration to market deutetrabenazine in early 2017, along with five years of orphan drug exclusivity for the treatment of chorea associated with Huntington's disease. It was the first deuterated drug to receive FDA approval.[6][7][8]
See also
References
- ↑ 1.0 1.1 "Austedo". 9 June 2021. https://www.tga.gov.au/apm-summary/austedo.
- ↑ "AusPAR: Deutetrabenazine". 27 May 2022. https://www.tga.gov.au/auspar/auspar-deutetrabenazine.
- ↑ "Breakthrough drugs for the interface between psychiatry and neurology". International Journal of Clinical Practice 70 (4): 298–299. April 2016. doi:10.1111/ijcp.12805. PMID 27028671. http://www.medscape.com/viewarticle/861499. Retrieved 4 April 2017.
- ↑ "Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease". Drugs 77 (1): 29–46. January 2017. doi:10.1007/s40265-016-0670-4. PMID 27988871.
- ↑ "Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial". The Lancet. Psychiatry 4 (8): 595–604. August 2017. doi:10.1016/S2215-0366(17)30236-5. PMID 28668671. http://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(17)30236-5/fulltext. Retrieved 4 February 2018.
- ↑ "FDA Approves Drug for Huntington's Disease". 3 April 2017. http://www.raredr.com/news/fda-approves-drug-for-huntingtons-chorea.
- ↑ "First deuterated drug approved". Nature Biotechnology 35 (6): 493–494. June 2017. doi:10.1038/nbt0617-493. PMID 28591114.
- ↑ "FDA Determines that Deuterated Compounds are NCEs and Different Orphan Drugs Versus Non-deuterated Versions". 16 July 2017. http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2017/07/fda-determines-that-deuterated-compounds-are-nces-and-different-orphan-drugs-versus-non-deuterated-v.html.
Further reading
- "Deutetrabenazine Therapy and CYP2D6 Genotype". Medical Genetics Summaries. National Center for Biotechnology Information (NCBI). May 2019. https://www.ncbi.nlm.nih.gov/books/NBK540716/.
External links
- "Deutetrabenazine". Drug Information Portal. U.S. National Library of Medicine. https://druginfo.nlm.nih.gov/drugportal/name/deutetrabenazine.
 |  |
